Actively Recruiting

Phase 2
Phase 3
Age: 50Years +
All Genders
NCT07496567

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

Led by EyeBiotech Ltd. · Updated on 2026-05-04

960

Participants Needed

9

Research Sites

119 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.

CONDITIONS

Official Title

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)
  • The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment
  • Age 50 years or older
Not Eligible

You will not qualify if you...

  • Has uncontrolled blood pressure at screening
  • History of any prior macular laser photocoagulation in the study eye
  • History of uveitis in either eye
  • History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study
  • Has uncontrolled glaucoma in the study eye
  • Active retinal disease other than the condition under investigation in the study eye
  • Has previously received anti-vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

Northern California Retina Vitreous Associates Medical Group, Inc.

Mountain View, California, United States, 94040

Actively Recruiting

2

University Retina & Macula Associates, P.C.

Lemont, Illinois, United States, 60439

Actively Recruiting

3

Mid Atlantic Retina Specialists

Hagerstown, Maryland, United States, 21740

Actively Recruiting

4

Retina Consultants of Minnesota

Edina, Minnesota, United States, 55435

Actively Recruiting

5

Envision Ocular, LLC

Bloomfield, New Jersey, United States, 07003

Actively Recruiting

6

Erie Retina Research

Erie, Pennsylvania, United States, 16505

Actively Recruiting

7

Charleston Neuroscience Institute

Ladson, South Carolina, United States, 29456

Actively Recruiting

8

Retina Consultants of Texas

Bellaire, Texas, United States, 77401

Actively Recruiting

9

Pacific Northwest Retina

Bellevue, Washington, United States, 98004

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) | DecenTrialz